期刊
BIOLOGICAL PSYCHIATRY
卷 73, 期 12, 页码 1125-1132出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2013.01.021
关键词
AMPA; depression; GLT-1; mGlu2/3; mGlu5; mGlu7; NMDA; x(c)(-)
资金
- Institute of Pharmacology, Polish Academy of Sciences, Krakow
- Task 3.7 [POIG.01.01.0212-004/09-00]
Over the past 20 years, converging lines of evidence have both linked glutamatergic dysfunction to the pathophysiology of depression and demonstrated that the glutamatergic synapse presents multiple targets for developing novel antidepressants. The robust antidepressant effects of the N-methyl-D-aspartate receptor antagonists ketamine and traxoprodil provide target validation for this family of ionotropic glutamate receptors. This article reviews the preclinical evidence that it may be possible to develop glutamate-based antidepressants by not only modulating ionotropic (N-methyl-D-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid) and metabotropic glutamate (mGlu) receptors, including mGlu2/3, mGLu5 and mGlu7 receptors, but also by altering synaptic concentrations of glutamate via specialized transporters such as glial glutamate transporter 1 (excitatory amino-acid transporter 2).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据